UK's Association of British Clinical Diabetologist's Diabetes Technology Network (ABCD-DTN): Best practice guide for hybrid closed-loop therapy.
artificial pancreas
automated insulin delivery systems
continuous glucose monitoring
hybrid closed loop
insulin pumps
type 1 diabetes
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
27
02
2023
received:
18
01
2023
accepted:
28
02
2023
medline:
20
6
2023
pubmed:
19
3
2023
entrez:
18
3
2023
Statut:
ppublish
Résumé
This best practice guide is written with the aim of providing an overview of current hybrid closed-loop (HCL) systems in use within the United Kingdom's (UK) National Health Service (NHS) and to provide education and advice for their management on both an individual and clinical service level. The environment of diabetes technology, and particularly HCL systems, is rapidly evolving. The past decade has seen unprecedented advances in the development of HCL systems. These systems improve glycaemic outcomes and reduce the burden of treatment for people with type 1 diabetes (pwT1D). It is anticipated that access to these systems will increase in England as a result of updates in National Institute of Health and Care Excellence (NICE) guidance providing broader support for the use of real-time continuous glucose monitoring (CGM) for pwT1D. NICE is currently undertaking multiple-technology appraisal into HCL systems. Based on experience from centres involved in supporting advanced technologies as well as from the recent NHS England HCL pilot, this guide is intended to provide healthcare professionals with UK expert consensus on the best practice for initiation, optimisation and ongoing management of HCL therapy.
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Practice Guideline
Research Support, Non-U.S. Gov't
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15078Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
Références
Leelarathna L, Choudhary P, Wilmot EG, et al. Hybrid closed-loop therapy: where are we in 2021? Diabetes Obes Metab. 2021;23(3):655-660.
Phillip M, Nimri R, Bergenstal RM, et al. Consensus recommendations for the use of automated insulin delivery (AID) technologies in clinical practice. Endocr Rev. 2022;44(2):254-280.
Braune K, Lal RA, Petruželková L, et al. Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. Lancet Diabetes Endocrinol. 2022;10(1):58-74.
Diabetes control and complications trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care. 1987;10(1):1-19.
Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15(3):205-218.
National Diabetes Audit. Report 1: Care Processes and Treatment Targets 2020-21, Full Report. Published 14 July 2022. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/core-report-1-2020-21. Accessed 21 December 2022.
Breton MD, Kovatchev BP. One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021;23(9):601-608.
Silva JD, Lepore G, Battelino T, et al. Real-world performance of the MiniMed™ 780G system: first report of outcomes from 4120 users. Diabetes Technol Ther. 2022;24(2):113-119.
Tauschmann M, Thabit H, Bally L, et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018;392(10155):1321-1329.
Knoll C, Peacock S, Wäldchen M, et al. Real-world evidence on clinical outcomes of people with type 1 diabetes using open-source and commercial automated insulin dosing systems: a systematic review. Diabet Med. 2022;39(5):e14741.
Usoh CO, Johnson CP, Speiser JL, Bundy R, Dharod A, Aloi JA. Real-world efficacy of the hybrid closed-loop system. J Diabetes Sci Technol. 2022;16(3):659-662.
Hartnell S, Fuchs J, Boughton CK, Hovorka R. Closed-loop technology: a practical guide. Pract Diabetes. 2021;38(4):33-39.
Boughton CK, Hovorka R. New closed-loop insulin systems. Diabetologia. 2021;64(5):1007-1015.
Crabtree TSJ, Griffin T, Lumb A, et al. Protocol for the Diabetes Technology Network UK and Association of British Clinical Diabetologists' closed-loop insulin delivery audit programme. Br J Diabetes 2022;22(1):9-13.
National Institute for Health and Care Excellence (NICE). Type 1 Diabetes in Adults: Diagnosis and Management (NG17). NICE guideline. Published: 26 August 2015. Last updated 17 August 2022. www.nice.org.uk/guidance/ng17
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes [GID-TA10845]. https://www.nice.org.uk/guidance/indevelopment/gid-ta10845. Accessed 14 February 2022.
Sherr JL, Heinemann L, Fleming GA, et al. Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia. 2022;66(1):3-22.
Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study. Diabetes Care. 2022;45(3):750-753.
Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9-16.
Efficacy and safety of tandem control IQ without user-initiated boluses in adults with uncontrolled type 1 diabetes. Diabetes Technol Ther. 2022;24(10):779-783.
Messer LH, Berget C, Forlenza GP. A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm. Diabetes Technol Ther. 2019;21(8):462-469.
Lewis DM, Hussain S. Practical guidance on open source and commercial automated insulin delivery systems: a guide for healthcare professionals supporting people with insulin-requiring diabetes. Diabetes Therapy. 2022;13(9):1683-1699.
Virtual showroom. https://abcd.care/dtn/virtual-showroom. Accessed 30 October 2022.
DTN-UK Education: Expert views on devices. https://abcd.care/dtn-education/expert-views-on-devices. Accessed 30 October 2022.
Hood KK, Laffel LM, Danne T, et al. Lived experience of advanced hybrid closed-loop versus hybrid closed-loop: patient-reported outcomes and perspectives. Diabetes Technol Ther. 2021;23(12):857-861.
Pinsker JE, Müller L, Constantin A, et al. Real-world patient-reported outcomes and glycemic results with initiation of control-IQ technology. Diabetes Technol Ther. 2021;23(2):120-127.
Hood KK, Garcia-Willingham N, Hanes S, et al. Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents. Diabetes Obes Metab. 2022;24(12):2309-2318.
https://www.england.nhs.uk/long-read/the-six-principles-of-good-peer-support-for-people-living-with-type-1-diabetes/. Accessed 21 December 2022.
The commencement of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) remotely-A DTN-UK guideline. https://abcd.care/sites/abcd.care/files/site_uploads/Resources/DTN/DTN-Remote-Start-SOP.pdf. Accessed 30 October 2022.
Best Practice Guide: Continuous subcutaneous insulin infusion (CSII): A clinical guide for adult diabetes services. https://abcd.care/sites/abcd.care/files/BP_DTN_v13%20FINAL.pdf. Accessed 30 October 2022.
Boughton CK, Hartnell S, Allen JM, Fuchs J, Hovorka R. Training and support for hybrid closed-loop therapy. J Diabetes Sci Technol. 2022;16(1):218-223.
Swift PG, Skinner TC, de Beaufort CE, et al. Target setting in intensive insulin management is associated with metabolic control: the Hvidoere childhood diabetes study group Centre differences study 2005. Pediatr Diabetes. 2010;11(4):271-278.
Choudhary P, Lumb A, Wilmot E, Gallen G, Hartnell S, Cranston I, Elliott J. Insulin pump therapy pathway: DTN recommendations. Version 1.0. 19/04/2021.
Avari P, Lumb A, Flanagan D, et al. Insulin pumps and hybrid close loop systems within hospital: a scoping review and practical guidance from the joint British diabetes societies for inpatient care. J Diabetes Sci Technol. 2022. doi: 10.1177/19322968221137335
National Institute for Health and Care Excellence. TA151 continuous subcutaneous insulin infusion for the Treatment of Diabetes Mellitus. 2008.
NICE Guideline in Development (GID-TA10845). Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. Apprsaisal consultation document: 10 January 2023.
Zaharieva DP, Messer LH, Paldus B, O'Neal DN, Maahs DM, Riddell MC. Glucose control during physical activity and exercise using closed loop technology in adults and adolescents with type 1 diabetes. Can J Diabetes. 2020;44(8):740-749.
Phillip M, Nimri R, Bergenstal RM, et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev. 2022;44(2):254-280.
Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol. 2017;5(5):377-390.
Adolfsson P, Riddell MC, Taplin CE, et al. ISPAD clinical practice consensus guidelines 2018: exercise in children and adolescents with diabetes. Pediatr Diabetes. 2018;19(Suppl 27):205-226.
Zaharieva DP, McGaugh S, Pooni R, Vienneau T, Ly T, Riddell MC. Improved open-loop glucose control with basal insulin reduction 90 minutes before aerobic exercise in patients with type 1 diabetes on continuous subcutaneous insulin infusion. Diabetes Care. 2019;42(5):824-831.
https://healthinnovationnetwork.com/wp-content/uploads/2017/01/Type-1-Consultation-Tool-User-Guide.pdf . Accessed 30 October 2022.